Vectura Company Overview and Profile

Vectura is a UK-based company that specializes in developing and commercializing inhaled respiratory products. Founded in 1997, Vectura has grown to become a leading player in the respiratory market.

Vectura's expertise lies in its proprietary dry powder inhaler (DPI) technology, which is designed to deliver precise and consistent dosing of medications directly to the lungs. This technology has been used in various products, including those for chronic obstructive pulmonary disease (COPD) and asthma.

Vectura has a strong portfolio of products, including Relvar/Breo Ellipta, a combination medication for COPD and asthma. This product has been approved in many countries and has received positive reviews from patients and healthcare professionals alike.

Vectura's products have been shown to improve lung function and quality of life for patients with respiratory diseases.

Vectura was formed in 1997 at the University of Bath as a start-up pharmaceuticals business.

The company's early years were marked by significant growth and expansion, with it acquiring Co-ordinated Drug Development and the Centre for Drug Formulation Studies in 1999.

Here's an interesting read: Meyer Brothers Drug Company

In 2002, Vectura moved from the university campus to a site at Chippenham, Wiltshire, marking a significant milestone in its development.

Vectura listed on the Alternative Investment Market in 2004, providing a boost to the company's profile and credibility.

In 2006, Vectura acquired Innovata Biomed plc, another developer of pulmonary products, further expanding its reach.

Vectura continued to grow, listing on the full list of the London Stock Exchange in 2006.

In 2014, the company made a significant acquisition, buying Activaero, a German manufacturer, for £108 million.

The merged company with Skyepharma in 2016 was a major turning point, creating a company with a strong presence in the sector.

Vectura decided to focus on inhaled products, leading to the sale of its oral products manufacturing site in Lyon, France, in 2021.

In December 2024, Vectura was acquired by the American manufacturing company Molex, a subsidiary of Koch, Inc.

Curious to learn more? Check out: Pension Protection Act of 2006

Vectura has a diverse portfolio of products that cater to various respiratory needs.

Vectura's products include a range of inhalation medicines for respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

Vectura's products have been approved by regulatory bodies such as the US FDA and the European Medicines Agency (EMA).

Vectura's inhalation medicines are designed to be easy to use and provide effective relief for patients suffering from respiratory conditions.

Vectura's products are available in various forms, including dry powder inhalers (DPIs) and soft mist inhalers (SMIs).

Vectura has a strong presence in the respiratory market with a presence in over 40 countries worldwide.

Vectura's products are used by millions of patients worldwide, providing them with relief from their respiratory symptoms.

Vectura's research and development efforts focus on developing innovative inhalation medicines that address unmet medical needs.

Vectura has a global network of partners and collaborators who help to advance the development of its products.

Vectura's commitment to innovation and patient needs has led to the development of several first-in-class products.

For more insights, see: Special Needs Trust Trustee

Vectura has a significant presence in the UK and Europe, with its headquarters and development facility located at Chippenham, England, employing around 250 people as of 2022.

The company also has development sites in Cambridge, Muttenz (Basel, Switzerland), and Gauting (Germany), which suggests a strong focus on international collaboration and innovation.

Vectura has received a total funding of $15.2 million over two rounds, with its first funding round taking place on April 24, 2001, and its latest funding round being a Post IPO round on November 26, 2007, for $21.8 million.

Here is a summary of Vectura's funding rounds:

The company's headquarters and development facility are located in Chippenham, England, on a mixed industrial site on the outskirts of the town.

As of 2022, around 250 people were employed at this location.

There are also development sites at Cambridge and Muttenz (Basel, Switzerland), as well as Gauting (Germany).

A new research & development building is planned for the Bristol and Bath Science Park, which could open in 2025.

Vectura has received a total of $15.2M in funding through two rounds. The first funding round was on April 24, 2001.

Vectura's latest funding round was a Post IPO round on November 26, 2007, which raised $21.8M. This round was led by a single investor, Boehringer Ingelheim.

Vectura has a total of 7 institutional investors, including HBM Healthcare Investments, EQT, and Boehringer Ingelheim. These investors have played a significant role in shaping the company's growth and development.

Here are the details of Vectura's funding rounds:

Molex has acquired UK-based inhalation drug device design and formulation company Vectura Group, expanding its capabilities in medical devices.

Vectura brings specialized inhalation expertise to the table, which will enhance Phillips Medisize's ability to deliver inhalation combination drug devices and solutions to pharmaceutical customers.

Phillips Medisize president Paul Chaffin sees this acquisition as a way to support the company's mission to help people live healthier, more productive lives.

For another approach, see: RF Micro Devices

The acquisition encompasses Vectura's services in pharmaceutical analysis, process development, technical transfer, clinical trial supplies, and regulatory services.

Vectura is involved in the formulation and device development of dry powder inhalers, pressurised metered-dose inhalers, and nasal and nebuliser products for various types of medications.

Molex CEO Joe Nelligan views the acquisition as a key step in building an industry-leading capability in medical devices.

The transaction is expected to be finalized by the end of 2024, pending regulatory approvals and other customary closing conditions.

Vectura's pipeline is filled with innovative medical products, including the Digitally-Connected LOMI Device, which is a dry powder inhaler device designed for use in the United States to treat Chronic Obstructive Pulmonary Disease (COPD).

Vectura's pipeline also includes the Flutiform pMDI, a metered dose inhaler device approved for use in China to treat asthma.

Vectura's FOX Vibrating Mesh Nebulizer is a nebulizer system being clinically tested in the United Kingdom for the treatment of Coronavirus Disease 2019 (COVID-19).

Vectura's pipeline products are at various stages of development, including early development, pre-clinical, clinical, and approval processes.

Here are the development stages of Vectura's pipeline products:

Vectura's commercial success hinges on its ability to stay ahead of the market, which it achieves by understanding the products that will be commercialized.

This allows Vectura to contend with the changing product portfolios of its competitors.

By uncovering what competitors do and how they do it, Vectura can adapt its strategies to remain competitive.

Vectura's focus on understanding market trends and competitor activity enables it to make informed decisions about its product offerings.

Consider reading: What Does Mou Stand for in Business